CERDIA – Cerivastatin in Diabetes Trial
Menno V. Huisman - Leiden University Medical Center, Leiden, the Netherlands
Edith Beishuizen - HMC+ (Bronovo), the Hague, the Netherlands
The Cerivastatin in Diabetes Trial (CERDIA) is a two-arm clinical trial based at the Hague, the Netherlands. The principal aim of the trial was to investigate the effect of Cerivastatin (0.4mg/day), which was later replaced by Simvastatin (20mg/day), versus placebo on the process of atherosclerosis in non-insulin dependent diabetes mellitus. Individuals were identified when attending the Leyenburg Hospital and the Red Cross Hospital, the Hague and were eligible for inclusion if they were aged between 30 and 80 years, had been diagnosed with type 2 diabetes for at least one year, and were without a history of cardiovascular disease. The study was approved by the medical ethics committees of both hospitals.
Link to study webpage – https://www.trialregister.nl/trial/250
Two-Year Statin Therapy Does Not Alter the Progression of Intima-Media Thickness in Patients With Type 2 Diabetes Without Manifest Cardiovascular Disease. Diabetes Care. 2004 Dec;27(12):2887-92
The Effect of Statin Therapy on Endothelial Function in Type 2 Diabetes Without Manifest Cardiovascular Disease. Diabetes Care. 2005 Jul;28(7):1668-74